Editorial, page 658 SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles ABSTRACT Objective: To identify the genetic etiology and characterize the clinicopathologic features of a novel distal myopathy.
myopathies, VCP myopathy has rimmed vacuoles (RVs) and aggregates of proteins such as SQSTM1 and TAR DNA-binding protein 43 (TDP-43). 5, 6 Mutations in SQSTM1 and TARDP are associated with ALS, leading to speculation about a genetic and pathogenic overlap between rimmed vacuolar myopathies and ALS. 7, 8 This is further supported by the identification of mutations in HNRNPA2B1 and HNRNPA1 as causing varied phenotypic penetrance of IBM and ALS. 9 Whether mutations in other genes can similarly lead to phenotypes consisting of muscle, bone, and CNS dysfunction is not established.
METHODS Patient selection and evaluation. Patients
with muscle weakness of unknown genetic cause were identified from the Washington University Neuromuscular Genetics Project and from the international cohort of undetermined distal myopathies at the Neuromuscular Research Center in Finland. Charts, clinical records, and pathology were reviewed, and available individuals were reexamined.
Standard protocol approvals, registrations, and patient consents. All participants gave written informed consent, and study procedures were approved by the Human Studies Committee at Washington University and the Institutional Review Board of the Helsinki University Hospital.
Histochemistry and immunohistochemistry. Muscle tissue was processed as previously described. 10 Cryostat sections of frozen muscle were processed and fixed in acetone. Antibodies used were anti-TDP-43 (Proteintech, Chicago, IL) and anti-SQSTM1 (Sigma-Aldrich, St. Louis, MO) for immunohistochemistry, anti-SQSTM1 (Proteintech) for immunoblot, and anti-ubiquitin (Enzo Life Sciences BML-PW8810, Farmingdale, NY), antiactin rabbit polyclonal antibody (Sigma-Aldrich), mouse anti-ubiquitin FK2 (Enzo Life Sciences BML-PW8810), rabbit anti-mCherry (Rockland Immunochemicals, Inc. 600-401-P16S, Pottstown, PA), rabbit anti-GAPDH antibody (Cell Signaling Technology 2118, Danvers, MA), and LC3 (NanoTools, Teningen, Germany). U2OS cells were cultured on coverslips and transfected using Lipofectamine 2000 (Invitrogen, Waltham, MA). Transfected cells were washed with phosphatebuffered saline (PBS) and fixed in 3.7% paraformaldehyde for 10 minutes, washed in PTB (1x PBS, 0.1% Triton X-100, 0.1% bovine serum albumin), incubated in primary antibodies at a 1:100 dilution at 4°C overnight, and washed with PTB buffer. Cells were incubated with Alexa Fluor 488 goat anti-mouse secondary antibody (Invitrogen) at a 1:1,000 dilution and washed as above. Coverslips were mounted on slides using Mowiol reagent containing 4',6-diamidino-2-phenylindole (1:1,000). Images were acquired with a CoolSNAP EZ camera on a Nikon Eclipse 80i microscope with NIS-Elements AR 3.00 software (Nikon, Tokyo, Japan). Mouse tibialis anterior (TA) electroporation and visualization were performed as previously described. 5 Electron microscopy. Muscle was fixed in modified Karnovsky fixative and processed as previously described. 5 Slides were viewed with a JEOL model 1200EX electron microscope (JEOL, Tokyo, Japan). Images were acquired using the AMT Advantage HR high-definition CCD, 1.3 megapixel transmission electron microscopy camera (Advanced Microscopy Techniques, Woburn, MA).
Whole-exome sequencing and targeted exome sequencing.
Indexed genomic DNA (gDNA) libraries were prepared from gDNA using TruSeq DNA Preparation Kit (Illumina, San Diego, CA) and exome capture using TruSeq Exome Enrichment Kit (Illumina), according to the manufacturer's protocol. Sequencing was performed with 100 bp paired-end reads on a HiSeq2000 (Illumina). For targeted sequencing, gDNA was captured using SeqCap EZ Choice Library (Roche NimbleGen, Madison, WI), which was designed to target exons of 180 myopathy-related genes. Sequencing was performed with 100 bp paired-end reads on a HiSeq1500 (Illumina) at the Institute for Molecular Medicine Finland. Reads were aligned to the human reference genome with NovoAlign or Burrows-Wheeler Aligner. Variants were called with SAMtools and annotated with SeattleSeq. Coverage across genomic intervals was calculated using BEDTools. Genomic coordinates for regions targeted by the whole-exome capture kit were provided by Illumina. Validation of mutations was assessed with standard PCR-based sequencing using Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/ primer3plus.cgi) for primer design, an Applied Biosystems 3730 DNA Sequencer (Life Technologies, Carlsbad, CA) for sequencing, and LaserGene SeqMan Pro version 8.0.2 (DNAStar, Madison, WI) for tracing analysis.
Primary fibroblast culture. Fibroblasts were cultured in Fibroblast Basal Medium FGM-2 CC-313 (Lonza, Basel, Switzerland) supplemented with CC-4126, as recommended by the manufacturer, at 37°C and 5% CO 2 in a humidified incubator.
RNA analysis. RNA was isolated from fibroblasts and muscle tissue using SV Total RNA Isolation Kit Z3100 (Promega, Madison, WI). Complementary DNA (cDNA) was prepared by reverse transcription PCR using Transcriptor First Strand cDNA Synthesis Kit from Roche (Basel, Switzerland), according to the manufacturer's instructions. cDNA was PCR amplified with primers specific for exon 7 and exon 9 of SQSTM1 using the following primers: forward primer 59-CAGCACAGAGGAGAAGAGCA-39 and reverse primer 59-GGGGATGCTTTGAATACTGG-39. PCR products were analyzed by electrophoresis, purified using QIAquick Gel Extraction Kit 28704 (Qiagen, Venlo, the Netherlands) and cloned into pGEM-T Easy Vector System (Promega). Colonies were sequenced with T7 Forward and SP6 Reverse primers.
Protein analysis. Muscle and fibroblasts were homogenized in radioimmunoprecipitation assay lysis buffer (50 mm Tris-HCl, pH 7.4, 150 mm NaCl, 1% NP-40, 0.25% Na-deoxycholate, and 1 mm ethylenediaminetetraacetic acid) supplemented with protease inhibitor cocktail (Sigma-Aldrich). Lysates were centrifuged at 14,000g for 10 minutes. Aliquots were solubilized in Laemmli sample buffer and equal amounts were separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels, transferred to nitrocellulose, and blocked with 5% nonfat dry milk in TBS-Tween. Membrane was incubated with antibody at 1:1,000 dilution overnight followed by incubation with secondary antibody conjugated with horseradish peroxidase at a 1:5,000 dilution. Amersham ECL Western Blotting Detection Reagents Kit (GE Healthcare, Chalfont St Giles, UK) was used for protein detection and immunoblots were visualized with G:Box Chemi XT4, Genesys version 1.1.2.0 (Syngene, Cambridge, UK).
RESULTS
Genetic findings. Whole-exome sequencing was performed on the proband of family 1 ( figure 1A) and targeted exome sequencing was performed on an unrelated patient with sporadic distal myopathy (figure 1B). No pathogenic variants in any gene associated with neuromuscular disease were identified. However, a heterozygous c.116511 G.A variant in SQSTM1 was present in both unrelated patients ( figure 1C ). This variant has a minor allele frequency of 0% in the Single Nucleotide Polymorphism database and the Exome Variant Server and has been previously reported in 2 families with AD PDB 11, 12 and in another single patient with sporadic ALS and PDB. 13 Sanger sequencing validated this variant in both patients and in the affected brother from family 1. No DNA was available from either patient's deceased parents.
Patient characteristics. Family 1. The proband, a 63year-old man from the United States, developed right ankle dorsiflexion weakness at age 52 and left ankle dorsiflexion weakness at age 57. At age 60 he noted left-greater-than-right "shoulder" weakness resulting in a referral to our institution. Past medical history included right hemidiaphragmatic paralysis, sequential bilateral cranial nerve VII palsies (right: age 38 with complete recovery; left: age 41 with residual weakness), and hypothyroidism. Family history (figure 1A) included his mother, who developed bilateral foot drop in her mid-60s and died at age 83, a similarly affected maternal uncle, and a brother with a similar phenotype (described below). His examination was notable for stigmata of a chronic left facial neuropathy, mild shoulder abduction weakness (left greater than right), bilateral scapular winging, left wrist extensor weakness, and bilateral ankle dorsiflexion and toe extension paresis with moderate plantar flexion weakness and severe toe flexion weakness. Ankle reflexes were absent with negative Babinski signs and a steppage gait. Creatine kinase (CK) was 419 U/L (normal 30-200 U/L) and alkaline phosphatase (ALP) was 87 U/L (normal 37-126 U/L). Nerve conduction studies (NCS) were normal. EMG showed a myopathy with myopathic features in the left extensor digitorum communis, first dorsal interosseous (FDI), abductor pollicis brevis, and right TA and medial gastrocnemius muscles. A radionuclide scan and plain film skeletal survey failed to identify any Pagetoid lesions. Transthoracic echocardiogram was normal. Forced vital capacity was 60% of predicted. Chromosome 4q35 deletion analysis for facioscapulohumeral dystrophy was negative. The proband's brother, now 47 years old, developed right ankle dorsiflexion weakness at age 42. At age 45 he had difficulty raising his right arm over his head and sought medical attention. His past medical history is notable for hypothyroidism and hypertension. On examination he had mild bilateral upper facial weakness. He had no scapular winging but did have inverted anterior axillary folds with mild bilateral pectoralis weakness. He had mild bilateral shoulder abduction and wrist extensor weakness, moderate ankle dorsiflexion weakness (right greater than left), and bilateral toe extensor weakness. Reflexes were normal with negative Babinski signs. Sensation and gait were unremarkable. CK was 143 U/L and ALP was 70 U/L. NCS were normal and EMG showed myopathic features in the left flexor pollicus longus and FDI muscles and the right extensor digitorum longus (EDL) and TA muscles. The right TA, EDL, and gastrocnemius also showed fibrillations and positive sharp waves, myotonic discharges, and complex repetitive discharges.
Patient with sporadic distal myopathy. The patient is a 60-year-old man from Australia with progressive distal lower extremity weakness. His symptoms began at age 50 when he developed a bilateral foot drop that progressed over the last 10 years to include finger extensor weakness and atrophy of his medial gastrocnemius muscles and shoulder girdle. He has no family history of muscle weakness, dementia, or PDB. On examination he had asymmetric scapular winging (left greater than right) and asymmetric shoulder weakness (right greater than left), mild hip flexor weakness, and marked weakness of bilateral ankle dorsiflexion and ankle eversion. CK was 346 U/L. He had no complaints of bone pain and his ALP was normal. NCS were normal and EMG was myopathic in his distal muscles. An MRI of his lower extremities demonstrated atrophy of his biceps femoris, soleus, medial gastrocnemius, and TA ( figure 1D ). Electron microscopy (EM) demonstrated large foci of myofibrillar disorganization and Z-band streaming (figure 2, G and H). Sporadic patient. Biopsy was remarkable for variation in fiber size, internal nuclei with fiber splitting, and scattered pyknotic nuclei. Occasional fibers were lobulated and scattered fibers contained multiple RVs. EM was consistent with a dystrophic process and myofibrillar disarray.
Splicing validation and protein studies. The c.116511 G.A variant in SQSTM1 alters a splice donor site at the exon-intron junction of exon 7 and is predicted to disrupt splicing of exon 7 to exon 8. We isolated cDNA from fibroblasts of a control and patient III.1 and PCR amplified exon 6 to exon 9 of SQSTM1. The amplified product from the control's fibroblasts migrated as a single band, consistent with intact exon 7-8 splicing ( figure 3A ). Patient III.1's amplified PCR product migrated as 3 bands: 1 matching the normally spliced messenger RNA and 2 others consistent with alternative splicing due to the utilization of cryptic splice acceptor sites ( figure 3A) . These PCR products were subcloned and sequenced to identify the cryptic splicing. In addition to the full-length SQSTM1 protein, 2 cryptically spliced SQSTM1 variants were identified in patient III.1's fibroblasts: a SQSTM1 deletion mutation p.G351_P388del (SQSTM1DPEST2) that utilized a cryptic splice acceptor within exon 7 and a SQSTM1 truncation mutation p.Glu389delinsAspLysTer (SQSTM1DUBA-DK) that utilized a cryptic splice acceptor within intron 7 ( figure 3, B and E) . These transcripts were also identified in patient III.1's muscle tissue (not shown). To confirm that the truncated and/or deleted SQSTM1 proteins were translated, we immunoblotted for SQSTM1 in fibroblasts from a control and patient III.1. As expected, full-length SQSTM1 was present in control lysates, but patient III.1's lysates contained the fulllength protein and a smaller SQSTM1 species migrating at the molecular weight of the predicted deletion and truncating mutants (figure 3C, lower blot). There was also an increase in high-molecularweight ubiquitin conjugates in patient fibroblasts compared with control fibroblasts (figure 3C, upper blot). Similar to patient fibroblasts, lysate from patient III.1's skeletal muscle showed a decrease in full-length SQSTM1 and the appearance of truncated SQSTM1 species (SQSTM1D) ( figure 3D ). The molecular weight of SQSTM1D in patient tissue was consistent with the predicted sizes of the 2 truncated SQSTM1 proteins that migrate similarly on immunoblot (figure 3, E and F).
The cellular localization of full-length SQSTM1, SQSTM1DUBA-DK, or SQSTM1DPEST2 fused to an N-terminal mCherry protein was assessed in throughout the cytoplasm and excluded from the nucleus. It did not localize to LC3 or ubiquitin. SQSTM1DPEST2 accumulated as large perinuclear inclusions that contained both LC3 and ubiquitin ( figure 4, A and B) . To see whether these patterns of SQSTM1 expression were found in muscle, we electroporated mouse TA muscle with similar expression constructs ( figure 4C ). As expected, mCherry was diffuse throughout myofibers. Overexpressed full-length SQSTM1 was present within the sarcoplasm and also as subsarcolemmal inclusions often adjacent to myonuclei. SQSTM1DUBA-DK was present throughout the sarcoplasm and associated with myofibrillar structures. In contrast, SQSTM1DPEST2 was found only as large subsarcolemmal and sarcoplasmic inclusions. DISCUSSION We expand the genetic etiology of AD distal myopathies with RVs to include SQSTM1. In addition, we expand the phenotypes associated with SQSTM1 mutations to include myopathy. ADinherited mutations in SQSTM1 are associated with hereditary and sporadic forms of PDB, ALS, and FTD. 7, 11, 14 The identification of SQSTM1 mutations in sporadic disease is likely due to its reduced penetrance. 7, 15 Our report identified a c.116511 G.A transition in SQSTM1 that was initially identified in an Australian family with PDB 11 and later identified in a French family with PDB. 12 More recently, a 75-year-old French woman with sporadic ALS manifesting as progressive distal lower limb weakness and PDB was found to have a c.116511 G.A transition in SQSTM1. 13 Neuropathologic assessment found TDP-43 and perinuclear SQSTM1 inclusions within the spinal cord and frontal cortex. 13 TDP-43 and SQSTM1 inclusions are a pathologic feature seen in myopathies with RVs 6,16 and were similarly found in the skeletal muscle of our patient carrying a SQSTM1 mutation (figure 2, E and F). Notably, the patients described in this study did not have evidence of PDB, ALS, or FTD, suggesting that myopathy can occur in isolation with c.116511 G.A SQSTM1 variant. SQSTM1 is an adaptor that associates with ubiquitinated proteins and LC3 via its ubiquitinassociated (UBA) domain and LC3-interacting region to facilitate autophagic degradation. 17 SQSTM1 oligomerizes and also associates with another ubiquitin adaptor, neighbor of BRCA1 gene 1 (Nbr1), via its N-terminal Phox/Bem1p domain. 18 Nbr1 and SQSTM1 may act independently or together in the autophagic degradation of proteins. 19 SQSTM1 also regulates the Nrf2 antioxidant response pathway 20 and nutrient-sensed mTORC1 activity. 21 In skeletal muscle, SQSTM1 has more specialized roles. SQSTM1 complexes with the muscle-specific E3 ligase MuRF2 and Nbr1 on the giant sarcomeric protein titin to coordinate protein turnover. 22 Recently, it has been suggested that SQSTM1 and MuRF2 are necessary for the autophagic recycling of nicotinic acetylcholine receptors in skeletal muscle. 23 The c.116511 G.A transition in SQSTM1 leads to the generation of 2 abnormal protein species, both of which could be pathogenic (figure 3E). One species, missing a C-terminal PEST domain, is p. G351_P388del (SQSTM1DPEST2). SQSTM1 has 2 PEST domains with undefined function. PEST sequences are suggested to modulate protein stability since they are found on short-lived proteins. 24 The other translated protein species is an SQSTM1 truncation mutation, p.Glu389delinsAspLysTer (SQSTM1DUBA-DK). This species lacks the UBA domain and fails to associate with ubiquitinated proteins. 25 Two previous studies suggested that the c.116511 G.A transition in SQSTM1 generated only the SQSTM1DUBA-DK translation product, calling it SQSTM1-A390X. 11, 12 A subsequent study evaluated the c.116511 G.A transition in SQSTM1 from transcripts generated in the spinal cord of a patient with ALS and identified the SQSTM1 r.1052_1165del transcript, suggesting that only SQSTM1DPEST2 is produced. 13 Our study found that both SQSTM1DUBA-DK and SQSTM1DPEST2 are transcribed and translated into proteins.
When these truncation mutations were expressed in cells and muscle, their localization was distinct from wild-type SQSTM1 and from each other. SQSTM1DUBA-DK was diffuse throughout the cell and on striations in mouse skeletal muscle, consistent with its reported localization to titin's kinase domain. 22 In contrast, SQSTM1DPEST2 generated large cytoplasmic and sarcoplasmic inclusions containing ubiquitin and LC3. This pattern of SQSTM1 localization in skeletal muscle was reminiscent of that seen in our patient's muscle ( figure 2F) .
Several other SQSTM1 truncation mutations have been reported in patients with familial PDB, including Leu394Ter and Glu396Ter. 26 These truncated species also lack the C-terminal UBA domain but are not generated by cryptic splicing, supporting the hypothesis that SQSTM1DUBA-DK is the pathogenic species. However, missense mutations within the PEST2 domain of SQSTM1 have also been reported in sporadic and familial disease. 7, 27 Similar to mutations in VCP, HNRNPA2B1, and HNRNPA1, mutations in SQSTM1 can lead to several different disease phenotypes, including rimmed vacuolar myopathy, ALS, FTD, and PDB. 4, 9 Why some patients develop PDB or ALS and others develop a myopathy is unclear, but it may be related to the presence of other inherited genetic modifiers. Indeed, it has been suggested that an APOE e4 allele increases the penetrance of FTD in patients with VCP mutations. 28 Whether a similar genetic factor increases risk for myopathy remains to be determined.
The disparate phenotypes in muscle, brain, spinal cord, and bone are unified by the pathologic accumulation of ubiquitin and TDP-43. 6, 9 In some cases, SQSTM1, VCP, HNRNPA2B1, and HNRNPA1 also accumulate along with ubiquitin and TDP-43 in affected tissues. 9 These diseases have been categorized together using the nomenclature "multisystem proteinopathy" (MSP), with mutations in VCP causing MSP1, mutations in HNRNPA2B1 causing MSP2, and mutations in HNRNPA1 causing MSP3. 9 We have now demonstrated that SQSTM1 can cause a rimmed vacuolar myopathy in addition to ALS, FTD, and PDB and could thus be considered a multisystem proteinopathy or MSP4.
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